Navigation Links
FDA Approves Novel Melanoma Drug
Date:8/17/2011

WEDNESDAY, Aug. 17 (HealthDay News) -- The U.S. Food and Drug Administration on Wednesday gave its approval to Zelboraf (vemurafenib), a first-of-its-kind drug for the treatment of an often lethal form of melanoma.

The drug targets a gene mutation that's present in about half of melanomas, the deadliest form of skin cancer.

"Zelboraf is a huge step forward in the fight against metastatic melanoma and the advancement of treatment for the deadliest form of skin cancer," Dr. Anna Pavlick, director of the NYU Melanoma Program at the NYU Cancer Institute, New York City, said in a university statement. She took part in phase II and III trials of the drug and is an advisor to Zelboraf's maker, Genentech.

"The approval of Zelboraf will make a significant impact on the survival and outcomes of advanced melanoma patients," Pavlick added. "Patients taking the drug Zelboraf were 63 percent less likely to die from advanced melanoma than patients given standard chemotherapy alone," she noted.

Another expert agreed that Zelboraf may be a potent weapon against melanoma for some patients.

The drug's approval "represents a breakthrough accomplishment in targeting a therapy to a specific group of patients who can benefit," Wendy K.D. Selig, president and chief executive officer of the Washington, D.C.-based Melanoma Research Alliance, said in a statement.

The FDA approval is specifically for patients with melanoma tumors that express a gene mutation called BRAF V600E.

BRAF typically helps regulate cell growth, but the variant of BRAF targeted by Zelboraf "is the abnormal gene mutation that allows melanoma cancer cells to spread," Pavlick explained. "Since almost 50 percent of all melanoma tumors have the BRAF genetic mutation, this targeted drug therapy can be of great benefit to many patients."

Along with the drug, the FDA also approved a companion test (made by Roche Molecular Systems) that will help
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. FDA Approves Blood Thinner Brilinta for Heart Patients
2. FDA Approves Test That Spots Aggressive Breast Cancer
3. FDA Approves Test That Spots HER2-Positive Breast Cancers
4. FDA Approves Another New Drug to Fight Hepatitis C
5. FDA approves new drug for advanced melanoma
6. FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma
7. FDA Approves 1st New Lupus Drug in More Than 50 Years
8. FDA Approves First 3D Mammogram Device
9. FDA Approves First Pacemaker Deemed Safe During MRIs
10. FDA Approves First Drug to Prevent Premature Births
11. Swiss agency approves clinical trial of UCI-created neural stem cell therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves Novel Melanoma Drug
(Date:7/31/2014)... Daily Gossip reveals in its review that the Flat Belly ... loss tips. , The author of the new method ... to implement. Users don’t have to worry, as they will ... counting calories. , The Flat Belly Forever program was ... weeks weight loss program to help sufferers model the perfect ...
(Date:7/31/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... at 10 tips to help drug or alcohol addicts cope ... process, and one that former addicts and those who support ... Drug Rehabilitation’s CEO Per Wickstrom . , According ...
(Date:7/31/2014)... The study, The Truth Behind ... episode of care payments for four clinical areas—congestive heart ... replacements (hips and knees). Using the definition of ... Care Improvement program, the study examines these clinical areas ... the country. , “Our study reaffirms that, in most ...
(Date:7/30/2014)... 30, 2014 The Mesothelioma ... Penn's Abramson Cancer Center, will host a regional ... experts in the field of mesothelioma. September 26 marks ... is open to the public, and specifically aimed at ... who have been exposed to asbestos. , The conference ...
(Date:7/30/2014)... events experienced during deployment, returning National Guard soldiers ... if faced with civilian life setbacks, including job ... legal problemsall commonplace in military families. Results of ... School of Public Health are published online in ... , Alcohol abuse is a major concern for ...
Breaking Medicine News(10 mins):Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3Health News:Vets' alcohol problems linked to stress on the home front 2
... Company (NYSE: PG ) announced net sales growth of ... Organic sales were up five,percent, delivering at the mid-point of ... led by strong growth in the Beauty, Fabric,Care & Home ... earnings,per share increased 12 percent to $1.03 for the quarter., ...
... /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the "Company") ... device company that develops, manufactures and markets ... it will be attending the,Credit Suisse Asian ... Location: Beijing, China, China Medical ...
... Melting Pot Restaurants join,St. Jude Children,s Research Hospital in ... - Dec. 31 to "give thanks for the healthy ... not.", "From the beginning, our involvement with St. ... said Kendra Sartor, vice president,of brand development for The ...
... growth, the global fluoroscopy and mobile C-arms market is forecast to ... form a large chunk of total market, particularly in the developed ... Asia-Pacific. , ... San Jose, CA (PRWEB) October 29, ...
... campaign against the threat of Coronary Heart Disease joined by Royle Family ... ... Tomlinson has warned British men against the threat of Coronary Heart Disease ... that he did not take his heart health seriously in the past ...
... 28 Today the ... responded to a request ... to hold an unnecessary,debate., ... letters, please visit:, http://www.noonprop8.com/downloads/FSchubert102808.pdf ...
Cached Medicine News:Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 2Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 3Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 4Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 5Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 6Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 7Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 8Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 9Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 10Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 11Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 12Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 13Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 14Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 15Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 16Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 17Health News:The Melting Pot Joins St. Jude Children's Research Hospital(R) for the Fifth Annual Thanks and Giving(R) Campaign 2Health News:The Melting Pot Joins St. Jude Children's Research Hospital(R) for the Fifth Annual Thanks and Giving(R) Campaign 3Health News:Fluoroscopy and Mobile C-arms Unit Sales to Reach 9.6 Thousand Units by 2012, According to New Report by Global Industry Analysts 2Health News:Fluoroscopy and Mobile C-arms Unit Sales to Reach 9.6 Thousand Units by 2012, According to New Report by Global Industry Analysts 3Health News:Ricky Tomlinson Joins Lloydspharmacy Against Coronary Heart Disease 2Health News:Ricky Tomlinson Joins Lloydspharmacy Against Coronary Heart Disease 3
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
(Date:7/30/2014)... NEW YORK , July 30, 2014 ... of new products for oncology supportive care, announced that ... has been featured in an article on OncLive.com titled, ... Head and Neck Cancers."  Dr. Steve Sonis , ... the growing demand seen in the oncology community for ...
(Date:7/30/2014)... July 30, 2014 /PRNewswire-iReach/ -- This is a ... Chinese Heparin sodium (CAS 9041-08-1) & calcium (CAS ... information of Heparin sodium (CAS 9041-08-1) & calcium ... technology. The report then explores global and China,s ... calcium (CAS 37270-89-6) listing their product specification, capacity, ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5
... System provides anterior column support for single ... T1 to L5. The system consists of ... cages that are stacked to a desired ... Carbon Fiber Reinforced Polymer material emulates the ...
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
... Cage system is a carbon fiber reinforced ... and biologic functions of posterior lumbar interbody ... provides a device designed to meet the ... cancellous bone, the best possible bone for ...
... is highly adaptable and therefore suitable for ... to its extraordinary small outer diameter and ... of a simple but secure and reliable ... steering instruments around the corner. These characteristics ...
Medicine Products: